ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/KIT
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/KIT
19
trial(s) found.
NCT07293351
Advanced
Phase 1 / Phase 2
Recruiting
ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (
CA266-0008
)
AXL/MET/RET/VEGFR/ROS1/KIT inhibitor
AXL inhibitor
KIT inhibitor
MET inhibitor,type 2
RET inhibitor
ROS1 inhibitor
VEGFR2 inhibitor
bispecific PD-L1/VEGFA antibody
Clear cell renal cell carcinoma
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2109 - North Ryde - Macquarie University Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT07227415
Advanced
Phase 1 / Phase 2
Recruiting
AN INTERVENTIONAL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA (
C6461008
)
bispecific PD-1/VEGF antibody
+ KIT inhibitor
Clear cell renal cell carcinoma
Kidney cancer
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
NCT07227402
Curative
Phase 3
Recruiting
A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (
LITESPARK-033
)
HIF2a inhibitor
MET/VEGFR2/AXL/MER inhibitor
+ AXL/MET/RET/VEGFR/ROS1/KIT inhibitor
Clear cell renal cell carcinoma
NSW
2109 - North Ryde - Macquarie University Hospital
NCT07218926
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) Versus Sunitinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) After Imatinib Therapy (StrateGIST 3)
BCR-ABL1 inhibitor,first generation
KIT inhibitor
PDGFRA inhibitor
Gastrointestinal stromal tumour
NSW
2145 - Westmead - The Children's Hospital at Westmead
ACT
2605 - Garran - The Canberra Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
NCT07011719
Advanced
Phase 3
Recruiting
A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma (
PEAK-1
)
AXL/MET/RET/VEGFR/ROS1/KIT inhibitor
AXL inhibitor
KIT inhibitor
MET inhibitor,type 2
RET inhibitor
ROS1 inhibitor
VEGFR2 inhibitor
placebo
Clear cell renal cell carcinoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4032 - Chermside - Icon Cancer Care Chermside
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
TAS
7000 - Hobart - ICON Cancer Care Hobart
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3010 - Rotorua - Rotorua Hospital
NZ.3210 - Hamilton - Waikato Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT06824168
Haem
Phase 2
Recruiting
A Phase 2, Multicenter, Randomized, Open-label Trial to Evaluate Safety and Efficacy of Two Dose Levels of Quizartinib as Maintenance for Adult Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia in Complete Remission (
AC220-167
)
FLT3 inhibitor
KIT inhibitor
Acute myeloid leukaemia
Leukaemia
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
NA
NA
NCT06578247
Haem
Phase 3
Recruiting
Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial Of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy and Administered as Maintenance Therapy in Adult Patients With Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia (
QuANTUM-WILD
)
placebo
+ KIT inhibitor
Leukaemia
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2139 - Concord - Concord Repatriation General Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
NCT06124157
Paed
Phase 2
Recruiting
An International Phase 2 Study of Chemotherapy and Tyrosine Kinase Inhibitors With Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-Class Philadelphia Chromosome-Like B-Cell Acute Lymphoblastic Leukemia (
NCI-2023-09214
)
bispecific T-cell engager,CD19-targeting
+ KIT inhibitor
Acute lymphoblastic leukaemia
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT05691478
Advanced
Phase 2 / Phase 3
Recruiting
A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination With Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma (
NCI-2022-08567
)
AXL/MET/RET/VEGFR/ROS1/KIT inhibitor
AXL inhibitor
KIT inhibitor
MET inhibitor,type 2
RET inhibitor
ROS1 inhibitor
VEGFR2 inhibitor
Osteosarcoma
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT05536141
Advanced
Phase 1
Recruiting
A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors (
ARC-20
)
HIF2a inhibitor
+ AXL/MET/RET/VEGFR/ROS1/KIT inhibitor
Clear cell renal cell carcinoma
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
NA
NA
NCT05327686
Radonc
Phase 2
Recruiting
Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (
SAMURAI
)
radiotherapy
+ AXL/MET/RET/VEGFR/ROS1/KIT inhibitor
Clear cell renal cell carcinoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT04996875
Haem
Phase 2
Recruiting
A Phase 2 Open-Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients With Advanced Systemic Mastocytosis (
2024-511407-42-00--CGT9486-20-201
)
KIT D816V inhibitor
KIT inhibitor,type 1
Haematological malignancy
Mast cell leukaemia
Systemic mastocytosis
NSW
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3051 - North Melbourne - Melbourne Theranostic Innovation Centre
QLD
4215 - Southport - Gold Coast University Hospital
NCT04625907
Radonc
Phase 1 / Phase 2
Recruiting
FaR-RMS
: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
Cyclophosphamide
Dactinomycin
Doxorubicin
FGFR1/2/3 inhibitor
FGFR1 inhibitor
FGFR2 inhibitor
FGFR3 inhibitor
FGFR4 inhibitor
FGFR inhibitor
Ifosfamide
Irinotecan
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
KIT inhibitor
KIT inhibitor,first generation
PDGFR inhibitor
RET inhibitor
Radiotherapy
Regorafenib
Temozolomide
VEGFR inhibitor
Vincristine
Vinorelbine
alkylating agent
anthracycline
antineoplastic antibiotic
cancer therapy
cancer therapy,FGFR-targeting
cancer therapy,FGFR1-targeting
cancer therapy,FGFR1/2/3-targeting
cancer therapy,FGFR2-targeting
cancer therapy,FGFR3-targeting
cancer therapy,FGFR4-targeting
cancer therapy,KIT-targeting
cancer therapy,PDGFR-targeting
cancer therapy,RET-targeting
cancer therapy,VEGFR-targeting
cytotoxic chemotherapy
pan-FGFR inhibitor
pan-FGFR inhibitor,reversible
topoisomerase inhibitor
vinca alkaloid
+ KIT/PDGFR/RET/VEGFR/FGFR inhibitor
Rhabdomyosarcoma
NSW
2031 - Randwick - Sydney Children's Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Children's Hospital at Westmead
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT03970447
Radonc
Phase 2 / Phase 3
Recruiting
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM (
GBM-AGILE
)
ATM inhibitor
AZD1390
Dianhydrogalactitol
FGFR1/2/3 inhibitor
FGFR1 inhibitor
FGFR2 inhibitor
FGFR3 inhibitor
FGFR4 inhibitor
FGFR inhibitor
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
KIT inhibitor
KIT inhibitor,first generation
Lomustine
PDGFR inhibitor
PI3K alpha inhibitor
PI3K delta inhibitor
PI3K inhibitor
Paxalisib
Pegargiminase
RET inhibitor
Radiotherapy
Regorafenib
Temozolomide
Troriluzole
VEGFR inhibitor
alkylating agent
arginine deiminase-polyethylene glycol conjugate
cancer therapy
cancer therapy,ATM-targeting
cancer therapy,FGFR-targeting
cancer therapy,FGFR1-targeting
cancer therapy,FGFR1/2/3-targeting
cancer therapy,FGFR2-targeting
cancer therapy,FGFR3-targeting
cancer therapy,FGFR4-targeting
cancer therapy,KIT-targeting
cancer therapy,PDGFR-targeting
cancer therapy,PI3K-targeting
cancer therapy,PI3K delta-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,RET-targeting
cancer therapy,VEGFR-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
dual PI3K/mTOR inhibitor
glutamate modulator
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
pan-FGFR inhibitor
pan-FGFR inhibitor,reversible
+ KIT/PDGFR/RET/VEGFR/FGFR inhibitor
Glioblastoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
ACTRN12624000532505
Radonc
Phase 3
Recruiting
International clinical research programme to improve outcomes in newly diagnosed Ewing sarcoma – Trial 1 (
INTER-EWING-1
)
Cyclophosphamide
Doxorubicin
Etoposide
FGFR1/2/3 inhibitor
FGFR1 inhibitor
FGFR2 inhibitor
FGFR3 inhibitor
FGFR4 inhibitor
FGFR inhibitor
Ifosfamide
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
KIT inhibitor
KIT inhibitor,first generation
PDGFR inhibitor
RET inhibitor
Radiotherapy
Regorafenib
VEGFR inhibitor
Vincristine
Vinorelbine
alkylating agent
anthracycline
cancer therapy
cancer therapy,FGFR-targeting
cancer therapy,FGFR1-targeting
cancer therapy,FGFR1/2/3-targeting
cancer therapy,FGFR2-targeting
cancer therapy,FGFR3-targeting
cancer therapy,FGFR4-targeting
cancer therapy,KIT-targeting
cancer therapy,PDGFR-targeting
cancer therapy,RET-targeting
cancer therapy,VEGFR-targeting
cytotoxic chemotherapy
pan-FGFR inhibitor
pan-FGFR inhibitor,reversible
topoisomerase inhibitor
vinca alkaloid
+ KIT/PDGFR/RET/VEGFR/FGFR inhibitor
Ewing sarcoma
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12623001338651
Haem
Phase 2
Recruiting
CML14 (ASCENDANCE) - ASCiminib Evaluation in Newly diagnosed CML with Dasatinib to Augment response in Complex genomic Etiology (
CML14-ASCENDANCE
)
BCR-ABL1 inhibitor
+ KIT inhibitor
Chronic myelogenous leukaemia
ACTRN12621000611820
Advanced
Phase 2
Recruiting
Prostate-Specific Membrane Antigen (PSMA) Intensity Can be Altered by Androgen and phospho-SrC Obstruction (
PICAASO
)
BCR-ABL1 inhibitor
BCR-ABL1 inhibitor,second generation
Dasatinib
KIT inhibitor
PDGFRA inhibitor
SRC inhibitor
YES1 inhibitor
cancer therapy
cancer therapy,BCR-ABL1-targeting
cancer therapy,KIT-targeting
cancer therapy,PDGFRA-targeting
cancer therapy,SRC-targeting
cancer therapy,YES1-targeting
+ KIT inhibitor
Castrate-resistant prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT05805501
Advanced
Phase 2
paused
A Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma (
BO43936
)
KIT inhibitor,ATP-competitive
VEGFR/PDGFR inhibitor
Clear cell renal cell carcinoma
QLD
4575 - Birtinya - Sunshine Coast University Hospital
ACTRN12621000991819
Advanced
Not Applicable
Status unknown
A Feasibility Trial of Patient Derived Cell Culture (PDCC) Chemosensitivity in Head and Neck Carcinoma (HNC) (
PDCCiHNC
)
ALK inhibitor
ALK inhibitor,first generation
ATR inhibitor
BCR-ABL1 inhibitor
BCR-ABL1 inhibitor,second generation
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
CRAF/FLT3/KIT/PDGFR/VEGFR inhibitor
CRAF inhibitor
Carboplatin
Ceralasertib
Cisplatin
Crizotinib
Dactolisib
Dasatinib
Docetaxel
Doxorubicin
EGFR inhibitor
EGFR inhibitor,first generation
Erlotinib
Etoposide
FLT3 inhibitor
Fluorouracil
Gemcitabine
Itraconazole
JAK1/JAK2 inhibitor
JAK1 inhibitor
JAK2 inhibitor
KIT inhibitor
MET inhibitor
MET inhibitor,type 1
Methotrexate
PDGFRA inhibitor
PDGFR inhibitor
PI3K/mTOR inhibitor
PI3K inhibitor
Paclitaxel
Palbociclib
Pemetrexed
RAF inhibitor
ROS1 inhibitor
Ruxolitinib
SMO inhibitor
SRC inhibitor
Sorafenib
VEGFR inhibitor
Vinorelbine
Vistusertib
YES1 inhibitor
anthracycline
antifolate
antimetabolite
cancer therapy
cancer therapy,ALK-targeting
cancer therapy,ATR-targeting
cancer therapy,BCR-ABL1-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,CRAF-targeting
cancer therapy,EGFR-targeting
cancer therapy,FLT3-targeting
cancer therapy,JAK1-targeting
cancer therapy,JAK2-targeting
cancer therapy,KIT-targeting
cancer therapy,MET-targeting
cancer therapy,PDGFR-targeting
cancer therapy,PDGFRA-targeting
cancer therapy,PI3K-targeting
cancer therapy,RAF-targeting
cancer therapy,ROS1-targeting
cancer therapy,SMO-targeting
cancer therapy,SRC-targeting
cancer therapy,VEGFR-targeting
cancer therapy,YES1-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
fluoropyrimidine
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
platinum-based antineoplastic agent
taxane
topoisomerase inhibitor
vinca alkaloid
+ CRAF/FLT3/KIT/PDGFR/VEGFR inhibitor
Head and neck cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (17)
paused (1)
Status unknown (1)
Recruitment Country and State
NSW (13)
VIC (12)
QLD (11)
WA (7)
SA (4)
NZ (3)
ACT (1)
TAS (1)
Phase
Phase 1 (1)
Phase 1 / Phase 2 (3)
Phase 2 (7)
Phase 2 / Phase 3 (2)
Phase 3 (5)
Trial Type
Advanced (9)
Haem (4)
Radonc (4)
Curative (1)
Paed (1)
Cancer Therapy Class
KIT
100%
VEGFR
68%
RET
47%
PDGFR
42%
MET
37%
ROS1
37%
AXL
32%
VEGFR2
32%
PD-1/PD-L1
26%
BCR-ABL1
26%
PDGFRA
26%
CTLA4
21%
PD-1
21%
SRC
21%
YES1
21%
HIF2a
16%
FLT3
16%
FGFR
16%
FGFR1
16%
FGFR1/2/3
16%
FGFR2
16%
FGFR3
16%
FGFR4
16%
PD-L1
11%
VEGF
11%
PI3K
11%
mTOR
11%
mTORC1
11%
mTORC2
11%
VEGFA
5%
MER
5%
CD19
5%
ATM
5%
PI3K delta
5%
PI3Kalpha
5%
LAG3
5%
TIGIT
5%
ALK
5%
ATR
5%
CDK4
5%
CDK6
5%
CRAF
5%
EGFR
5%
JAK1
5%
JAK2
5%
RAF
5%
SMO
5%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (5)
2145 - Westmead - The Children's Hospital at Westmead (3)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (3)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (3)
4101 - South Brisbane - Queensland Children's Hospital (3)
6009 - Perth - Perth Children's Hospital (3)
2050 - Camperdown - Chris O'Brien Lifehouse (3)
2109 - North Ryde - Macquarie University Hospital (2)
3004 - Melbourne, Southbank - Alfred Health (2)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (2)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (2)
4215 - Southport - Gold Coast University Hospital (2)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (2)
NA
3128 - Box Hill - Box Hill Hospital - Eastern Health (2)
4102 - Woolloongabba - Princess Alexandra Hospital (2)
5042 - Bedford Park - Flinders Medical Centre (2)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (2)
2031 - Randwick - Sydney Children's Hospital (2)
3052 - Parkville - Royal Children's Hospital Melbourne (2)
NZ.1023 - Grafton - Starship Children's Hospital (2)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (1)
2605 - Garran - The Canberra Hospital (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
4032 - Chermside - Icon Cancer Care Chermside (1)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
7000 - Hobart - ICON Cancer Care Hobart (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
NZ.3010 - Rotorua - Rotorua Hospital (1)
NZ.3210 - Hamilton - Waikato Hospital (1)
6000 - Perth - Royal Perth Hospital (1)
2139 - Concord - Concord Repatriation General Hospital (1)
2170 - Liverpool - Liverpool Hospital (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
6150 - Murdoch - Fiona Stanley Hospital (1)
3168 - Clayton - Monash Medical Centre (1)
2031 - Randwick - Scientia Clinical Research Ltd (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
3051 - North Melbourne - Melbourne Theranostic Innovation Centre (1)
2305 - New Lambton Heights - John Hunter Children's Hospital (1)
3168 - Clayton - Monash Children's Hospital (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
4575 - Birtinya - Sunshine Coast University Hospital (1)
Cancer Type
Cancer
Solid tumour
Urogenital cancer
Clear cell renal cell carcinoma
Kidney cancer
Haematological malignancy
Leukaemia
Sarcoma
Myeloid leukaemia
Bone cancer
Gastrointestinal cancer
Gastrointestinal stromal tumour
Upper gastrointestinal cancer
Acute myeloid leukaemia
Acute lymphoblastic leukaemia
Lymphoid leukaemia
Osteosarcoma
Mast cell disorder
Mast cell leukaemia
Systemic mastocytosis
Rhabdomyosarcoma
Soft tissue sarcoma
Central nervous system cancer
Glioblastoma
Glioma
High-grade glioma
Malignant glioma
Neurological cancer
Ewing family of tumours
Ewing sarcoma
Primitive neuroectodermal tumour
Chronic leukaemia
Chronic myelogenous leukaemia
Castrate-resistant prostate cancer
Male genital cancers
Prostate adenocarcinoma
Prostate cancer
Head and neck cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy